The presence of anti-p53 antibodies in sera from patients with oesophageal carcinoma: correlation to treatment, tumour volume and survival.
| Autor: | Bergström S; Department of Oncology, University Hospital, Uppsala, Sweden., Dreilich M, Wagenius G, Brattström D, Larsson A, Hesselius P, Bergqvist M |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | In vivo (Athens, Greece) [In Vivo] 2004 Sep-Oct; Vol. 18 (5), pp. 615-20. |
| Abstrakt: | Background: A correlation between mutations in the p53 gene and the presence of anti-p53 antibodies in sera has been reported. The aim of the present study was to analyse anti-p53 antibodies in sera from patients with oesophageal carcinoma and their implications for clinical outcome and survival Patients and Methods: Between 1996 and 2002, patients treated for oesophageal carcinoma at the Department of Oncology, Uppsala University Hospital, Sweden, were asked to donate serum samples during treatment and follow-up. A total of 42 patients, with serum samples collected prior to therapy, were analysed for expressions of anti-p53 antibodies using a commercially available sandwich ELISA (Dianova, Hamburg, Germany). Results: Anti-p53 antibodies did not correlate with investigated laboratory parameters. No correlation between anti-p53 antibodies and tumour volume was found (n=31; r=0.08;p=0.66). Anti-p53 antibodies as a continuous variable was not associated with survival (p = 0.42). Neither was the presence of anti-p53 antibodies (according to defined cut-off of 1.1, provided by the manufacturer) associated with survival (p = 0.99). Conclusion: The presence of anti-p53 antibodies correlated neither to tumour volume nor to clinical parameters. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|